

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

06 Jul 2026

### Effects of GnRH Antagonist versus GnRH Agonist Protocol on ART outcomes in Poor ovarian Responders

#### Protocol summary

##### Summary

GnRH agonist protocol prevents premature ovulation and early corpus luteum. The disadvantages are taking high doses and prolonged stimulation of the ovaries to respond better that the eggs are smaller and lower quality recycled. Recently, GnRH antagonists have been used in the middle of the cycle to prevent premature LH surge in the early follicular phase and decreased during ovarian stimulation. In this study, the effect of GnRH antagonists is compared with the long protocol GnRH agonists in patients with poor ovarian response. 100 infertile patients selected with inclusion criteria (number of oocytes recovered in less than 5 ...) and exclusion criteria (presence of chronic diseases ...), they were randomly divided into two groups: GnRH antagonists and GnRH agonists. GnRH agonist group, use of oral LD on cycle's days 2-3 for 14-21 days, as they will consume in Cycle days 21 Busereline 500 µg (Superfact) subcutaneously. After down regulation, stimulation with HMG is started and continued until at least two follicles with a diameter over mm 18. Busereline will continue daily until HCG (IU 1000) injections. Antagonist group GnRH, when the follicle diameter mm 10 Cetorelix 0.25 mg subcutaneous injection start and continue would be to inject Day HCG. Fourteen days after oocyte retrieval a quantitative serum value of BHCG was obtained, with a result of >10 UI/L being considered positive. Pregnancy is confirmed by the presence of gestational sac in ultrasound 7-6 weeks.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201302271760N21**

Registration date: **2013-08-28, 1392/06/06**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2013-08-28, 1392/06/06

##### Registrant information

###### Name

Nargess Gholizadeh Pasha

###### Name of organization / entity

Fatemehzahra Infertility Reproductive Health Research Center, Babol University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 11 3236 2282

###### Email address

zahra@mubabol.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice chancellor for Research and Technology, Babol University of Medical Sciences

##### Expected recruitment start date

2013-03-20, 1391/12/30

##### Expected recruitment end date

2013-10-22, 1392/07/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effects of GnRH Antagonist versus GnRH Agonist Protocol on ART outcomes in Poor ovarian Responders

##### Public title

Effects of GnRH Antagonist versus GnRH Agonist Protocol

on ART outcomes in Poor ovarian Responders

### Purpose

Treatment

### Inclusion/Exclusion criteria

Inclusion criteria: Infertile women who underwent IVF process and poor ovarian response; The number of oocytes recovered in less than 5; Serum estradiol levels on the day of HCG injection is less than pg / ml 600; Serum FSH levels in Male than 3 mIU / ml 12; Has over 37 years of age; Cessation of ovarian cycles due to poor response. Exclusion criteria: Chronic diseases; Diabetes; Any endocrine disease; Submucosal polyps; Leiomyoma and uterine septum.

### Age

From **37 years** old to **45 years** old

### Gender

Female

### Phase

2-3

### Groups that have been masked

*No information*

### Sample size

Target sample size: **100**

### Randomization (investigator's opinion)

Randomized

### Randomization description

### Blinding (investigator's opinion)

Not blinded

### Blinding description

### Placebo

Not used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

The ethics committee of Babol University of Medical sciences

##### Street address

Ganjafroz Avenue, Babol University of Medical sciences

##### City

Babol

##### Postal code

##### Approval date

2013-02-05, 1391/11/17

##### Ethics committee reference number

ژ-پ/30/200

## Health conditions studied

### 1

#### Description of health condition studied

Poor ovarian Responders

#### ICD-10 code

E28.8

#### ICD-10 code description

Other ovarian dysfunction

## Primary outcomes

### 1

#### Description

Pregnancy

#### Timepoint

7-6 weeks to see the gestational sac

#### Method of measurement

Ultrasound

## Secondary outcomes

### 1

#### Description

Endometrial thickness

#### Timepoint

Day of HCG injection

#### Method of measurement

Ultrasound

### 2

#### Description

Estradiol levels

#### Timepoint

Day of HCG injection

#### Method of measurement

Ultrasound

### 3

#### Description

The number of oocytes recovered

#### Timepoint

Day puncture

#### Method of measurement

Laboratory

### 4

#### Description

The duration of ovarian stimulation

#### Timepoint

Duration of drug use

#### Method of measurement

Clinical

### 5

#### Description

No. of fertilized oocytes

#### Timepoint

Day of embryo transfer  
**Method of measurement**  
Laboratory

## 6

**Description**  
The amount of transferred embryos  
**Timepoint**  
Day of embryo transfer  
**Method of measurement**  
Laboratory

## 7

**Description**  
The number of canceled cycles  
**Timepoint**  
Before embryo transfer  
**Method of measurement**  
Clinical

## 8

**Description**  
Pregnancy than to transfer  
**Timepoint**  
16 days after embryo transfer  
**Method of measurement**  
Laboratory

## 9

**Description**  
The incidence of ovarian hyperstimulation syndrome (OHSS)  
**Timepoint**  
After puncture  
**Method of measurement**  
Clinical & Laboratory

## 10

**Description**  
The total amount of FSH  
**Timepoint**  
48 hours before puncture  
**Method of measurement**  
Laboratory

## **Intervention groups**

### 1

**Description**  
Intervention group: Agonist (3-2 days after onset of LD cycles lasting 21-14 days, take one tablet daily for 21 days and the cycle Busereline 500 µg (Super facts) will subcutaneously. Later down regulation, stimulation with HMG begin until at least follicle diameters exceeding 2 mm 18 will continue. supermodel facts will continue daily until IU 1000 HCG injection)  
**Category**

Treatment - Drugs

### 2

**Description**  
Control group: Antagonist (GnRH when the follicle diameter 10mm, reach to daily injections of HCG, Cetorelix 0.25 mg subcutaneously daily will)  
**Category**  
Treatment - Drugs

## **Recruitment centers**

### 1

**Recruitment center**  
**Name of recruitment center**  
Fatemehzahra Fertility & reproductive Health Reseach Center  
**Full name of responsible person**  
Samaneh Niksimaei  
**Street address**  
Fatemehzahra Fertility & reproductive Health Reseach Center, Noshirvani street  
**City**  
Babol

## **Sponsors / Funding sources**

### 1

**Sponsor**  
**Name of organization / entity**  
Vice Chancellor for Research and Technology, Babol University of Medical Sciences  
**Full name of responsible person**  
Dr. Ali Bijani  
**Street address**  
Ganjafroz Avenue, Babol University of Medical Sciences, Vice Chancellor for Research and Technology  
**City**  
Babol  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Vice Chancellor for Research and Technology, Babol University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
*empty*  
**Domestic or foreign origin**  
*empty*  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
*empty*

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Fatemehzahra Fertility & reproductive Health  
Research Center

**Full name of responsible person**

Nargess Gholizadeh Pasha

**Position**

M.A/Responsible for Public Affairs of Research Center

**Other areas of specialty/work****Street address**

Fatemehzahra Fertility & reproductive Health  
Research Center, Noshirvani street

**City**

Babol

**Postal code****Phone**

+98 11 1227 4881

**Fax**

+98 11 1227 4880

**Email**

ngh\_pa@yahoo.com

**Web page address**

+98 11 1227 4881

**Fax****Email**

zeinalmahtab@yahoo.com

**Web page address**

## Person responsible for updating data

### Contact

**Name of organization / entity**

Fatemehzahra Infertility Reproductive Health  
Research Center

**Full name of responsible person**

Nargess Gholizadeh Pasha

**Position**

M.A/Responsible for Public Affairs of Research Center

**Other areas of specialty/work****Street address****City**

Babol

**Postal code****Phone**

00

**Fax****Email**

ngh\_pa@yahoo.com

**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Fatemehzahra Infertility & reproductive Health  
Research Center

**Full name of responsible person**

Dr. Mahtab Zeinalzadeh

**Position**

Gynecologist

**Other areas of specialty/work****Street address**

Fatemehzahra Infertility & reproductive Health  
Research Center, Noshirvani street

**City**

Babol

**Postal code****Phone**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*